Skip to content

    Dhanuka Agritech

    DHANUKA
    Chemicals·3 Feb 2025
    Management Summary

    Dhanuka Agritech delivered a robust Q3 FY25 performance with double-digit revenue and profit growth, driven by new product introductions and strong market execution. The company also made a significant strategic acquisition of international rights for two agrochemical molecules from Bayer, signaling its intent for global expansion. Despite challenges from adverse weather and commodity price pressures, particularly affecting generic products, Dhanuka maintained strong margins and outlined plans for future growth through product innovation and market diversification.

    Highlights

    5

    • Double-digit growth in both top-line (10.42%) and bottom-line (PAT 21.33%) despite challenging environment.

    • EBITDA margin expanded significantly by 21.55% YoY to ₹75.56 crores.

    • Successful introduction and acceptance of new products (LaNevo, MYCORE Super, Roxa) driving volume growth (around 11.67%).

    • Strategic acquisition of international rights for two key molecules (iprovalicarb and triadimenol) from Bayer AG for ₹160 crores, enabling global expansion.

    • Gross margins remained strong and sustainable, with current levels exceptionally high around 40%.

    Concerns

    4

    • Low pest attack and low rainfall in the Rabi season impacted sales of some key fungicides.

    • Carryover inventory of chili from last season and low commodity prices resulted in fewer crop spaces.

    • Dahej manufacturing facility continues to operate at a loss (₹4.25 crores in Q3 FY25 and ₹12 crores for 9M FY25).

    • Generic products in the portfolio experienced a 'beating' in terms of price and volume due to unfavorable market conditions.

    What Changed2

    vs Q4 FY25

    Guidance items13 → 7 (-6)Risks discussed3 → 6 (+3)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹445.27 Cr+10.4%YoY
    2. 02EBITDA₹75.56 Cr+21.6%YoY
    3. 03PAT₹55.04 Cr+21.3%YoY
    4. 04Volume Growth11.7%
    5. 05Dahej Revenue₹4 Cr

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    M&A

    International rights to active ingredients iprovalicarb and triadimenol from Bayer AG

    acquisition · closed · Consideration ₹NaN (mixed)

    Liquidity

    Liquidity disclosed

    Internal accruals of INR 115 crores were used to fund part of the acquisition cost.

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Dahej Facility Revenue
    ₹60-70 crores
    		Medium
    Revenue
    Acquired Bayer Products Revenue
    ₹175-200 crores
    		Medium
    Volume Growth
    Volume Growth (ex-Bayer molecules)
    15%
    		Medium
    Gross Margin
    Gross Margin Sustainability
    38-39%
    		High
    New Product Launches
    Number of New Product Launches
    8
    		High
    Growth
    Acquired Bayer Products Growth
    15%
    		Medium
    Debt Repayment
    Acquisition Loan Repayment
    ₹50 crores
    		High

    Dahej Facility Profitability

    Next quarter
    CurrentEBITDA loss of ₹4.25 crores in Q3 FY25
    TargetReduced loss or break-even

    Why it matters

    Continued losses at Dahej impact overall profitability; improvement is key for operational efficiency.

    You see in Q3, the revenue is around INR 4 crores. And in 9 months, the revenue is around INR 26 crores. And in terms of EBITDA loss in Q3 is around INR 4.25 crores, and in 9 months is around INR 12 crores.

    How to verify

    key_financials.metrics[label='Dahej EBITDA Loss']

    Risks & concerns

    6
    RiskSeverity

    Low pest attack and low rainfall in Rabi season

    Disease appearance in potato, grapes, and chili was less, leading to lower sales of some key fungicides. — Management acknowledged

    medium

    Carryover inventory of chili and low commodity prices

    Resulted in fewer spaces in the crop for new products. — Management acknowledged

    medium

    Dahej manufacturing facility operating at a loss

    EBITDA loss of ₹4.25 crores in Q3 FY25 and ₹12 crores for 9M FY25. — Analyst acknowledged

    medium

    Generic products in the portfolio taking a beating

    Generic products across the industry have taken a sharp beating in terms of price and volume. — Management acknowledged

    medium

    Red rot disease in sugarcane

    The disease is widespread in North India's highest-yielding sugarcane variety (60238), covering over 75% of acreage, posing a disaster risk. — Analyst acknowledged

    high

    Potential impact of Chinese dumping if US tariffs reduce their exports

    If China cannot export to the US, Chinese prices for other countries might come down further, impacting market dynamics. — Analyst acknowledged

    medium

    Q&A highlights

    8

    “So, these 2 products, iprovalicarb and triadimenol, they both contribute about 55%-45% to the revenue. Iprovalicarb is the larger revenue contributor out of these 2 products. With respect to the brand name around triadimenol, so these were tried brand names in series of other products also with Bayer, and had Bayer's initial B-A-Y in some of these products attached. So, they cannot transfer these brands to Dhanuka. So, that was the reason not to acquire those brand names.”

    Clarifies the specific products acquired, the reason for not acquiring brand names, and the initial revenue split, which is crucial for understanding the acquisition's scope.

    asked by Himanshu Upadhyay

    3 min read7 chapters

    Detailed Narrative

    01

    Q3 FY25 Financial Performance Overview

    Dhanuka Agritech reported a strong Q3 FY25, with revenue from operations increasing by 10.42% YoY to ₹445.27 crores, compared to ₹403.24 crores in Q3 FY24. EBITDA saw a significant rise of 21.55% to ₹75.56 crores, up from ₹62.16 crores. Profit after tax also grew by 21.33% to ₹55.04 crores, against ₹45.37 crores in the prior year. Volume growth was approximately 11.67%, indicating a slight negative impact from pricing.

    02

    Strategic International Acquisition from Bayer AG

    The company acquired international rights for iprovalicarb and triadimenol from Bayer AG for approximately ₹160 crores, to be capitalized in Q4 FY25. This acquisition aims to expand Dhanuka's footprint across more than 20 countries, including Latin America, Europe, Middle East, Africa, and Asia. Management expects these products to contribute ₹175-200 crores in revenue by FY27 and grow at 15% year-on-year for the subsequent five years, with manufacturing of at least one product shifting to the Dahej plant.

    03

    New Product Introductions Drive Volume Growth

    Volume growth in Q3 FY25 was primarily driven by the successful introduction and market acceptance of new specialty products such as LaNevo (insecticide), MYCORE Super (soil health rejuvenator), Purge (Japanese herbicide), and Miyako (Japanese miticide). These products, along with a new 9(4) product Roxa for wheat weed control, have been well-received by farmers. In contrast, generic products in the portfolio experienced a 'beating' in terms of both price and volume due to unfavorable market conditions.

    04

    Dahej Manufacturing Facility Performance

    The Dahej manufacturing facility recorded a revenue of ₹4 crores in Q3 FY25 and ₹26 crores for the nine-month period. However, it continued to incur an EBITDA loss of ₹4.25 crores in Q3 FY25 and ₹12 crores for the nine-month period. While no new CAPEX is planned for Dahej currently, the company is focusing on developing new products in R&D and pursuing international registrations for existing products like bifenthrin to improve its utilization and profitability, targeting ₹60-70 crores revenue in FY26.

    05

    Gross Margin Stability and Raw Material Outlook

    Dhanuka's gross margins remained strong, with management stating that a range of 38-39% is sustainable in the long run. Current margins were exceptionally around 40% due to a decline in trade and raw material prices. While overall raw material prices are stable, some specific products like Cartap, Mancozeb, Chlorpyrifos, and Cypermethrin have seen price increases. Management anticipates no major changes in raw material prices in the near future.

    06

    Strategic Crop Focus and Portfolio Alignment

    The government's renewed focus on increasing acreage for cotton, pulses, and oilseeds presents a significant opportunity for Dhanuka. The company has a strong portfolio to service pulses for weed and insect management and expects its products like Targa Super and MYCORE Super to benefit from increased attention on cotton. Additionally, the correction in ethanol prices is expected to boost the sugarcane economy, where Dhanuka is also well-positioned.

    07

    Challenges in Rabi Season and Market Conditions

    The Rabi season faced challenges from low pest attacks and insufficient rainfall, leading to reduced sales of certain fungicides. Carryover inventory of chili and low commodity prices also limited crop space. December and January saw subdued offtakes due to low pest and disease pressure, particularly in North and West India. The company maintains a clean channel inventory policy, avoiding front-loading, unlike many industry players.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.